POS0367 IMPROVEMENT OF INDIVIDUAL MUCOCUTANEOUS MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB

MLA

V. Werth, et al. “Pos0367 Improvement of Individual Mucocutaneous Manifestations in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab.” Annals of the Rheumatic Diseases, vol. 81, May 2022, p. 436.2-437. EBSCOhost, https://doi.org/10.1136/annrheumdis-2022-eular.690.

APA

V. Werth, J. Wissmar, A. Strömbeck, R. Tummala, C. Kleoudis, & M. Albulescu. (2022). Pos0367 Improvement of Individual Mucocutaneous Manifestations in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab. Annals of the Rheumatic Diseases, 81, 436.2-437. https://doi.org/10.1136/annrheumdis-2022-eular.690

Chicago

V. Werth, J. Wissmar, A. Strömbeck, R. Tummala, C. Kleoudis, and M. Albulescu. 2022. “Pos0367 Improvement of Individual Mucocutaneous Manifestations in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab.” Annals of the Rheumatic Diseases 81 (May): 436.2-437. doi:10.1136/annrheumdis-2022-eular.690.